These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 27285322)

  • 21. Elevated erythropoietin mRNA and protein concentrations in the developing human eye.
    Patel S; Rowe MJ; Winters SA; Ohls RK
    Pediatr Res; 2008 Apr; 63(4):394-7. PubMed ID: 18356745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Overview of erythropoietin].
    Lacombe C; Mayeux P; Casadevall N
    Nephrologie; 1991; 12(5):221-6. PubMed ID: 1662784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythropoietin and the heart: physiological effects and the therapeutic perspective.
    Sanchis-Gomar F; Garcia-Gimenez JL; Pareja-Galeano H; Romagnoli M; Perez-Quilis C; Lippi G
    Int J Cardiol; 2014 Feb; 171(2):116-25. PubMed ID: 24377712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy.
    Cancarini A; Costagliola C; Dell'omo R; Romano M; Morescalchi F; Agnifili L; Ruggeri G; Semeraro F
    Minerva Endocrinol; 2014 Dec; 39(4):305-11. PubMed ID: 25371057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythropoietin and the vascular wall: the controversy continues.
    Jelkmann W; Elliott S
    Nutr Metab Cardiovasc Dis; 2013 Dec; 23 Suppl 1():S37-43. PubMed ID: 22682530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carbamylated erythropoietin mediates retinal neuroprotection in streptozotocin-induced early-stage diabetic rats.
    Liu X; Zhu B; Zou H; Hu D; Gu Q; Liu K; Xu X
    Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1263-72. PubMed ID: 25725621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erythropoietin exerts a neuroprotective function against glutamate neurotoxicity in experimental diabetic retina.
    Gu L; Xu H; Wang F; Xu G; Sinha D; Wang J; Xu JY; Tian H; Gao F; Li W; Lu L; Zhang J; Xu GT
    Invest Ophthalmol Vis Sci; 2014 Oct; 55(12):8208-22. PubMed ID: 25335981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Function, molecular structure and gene expression regulation of erythropoietin].
    Miyazaki H
    Nihon Rinsho; 1992 Aug; 50(8):1879-84. PubMed ID: 1433979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mechanism of erythropoietin action.
    Koury MJ; Bondurant MC
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):20-3. PubMed ID: 1656733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy.
    Semeraro F; Cancarini A; Morescalchi F; Romano MR; dell'Omo R; Ruggeri G; Agnifili L; Costagliola C
    Diabetes Metab; 2014 Dec; 40(6):445-51. PubMed ID: 24878492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erythropoietin and the heart: facts and perspectives.
    Mastromarino V; Volpe M; Musumeci MB; Autore C; Conti E
    Clin Sci (Lond); 2011 Jan; 120(2):51-63. PubMed ID: 20929439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
    Tanaka T; Nangaku M
    Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Landmark advances in the development of erythropoietin.
    Fisher JW
    Exp Biol Med (Maywood); 2010 Dec; 235(12):1398-411. PubMed ID: 21127338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hypertension-related eye disorders].
    Resch M; Süveges I; Németh J
    Orv Hetil; 2013 Nov; 154(45):1773-80. PubMed ID: 24184929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-angiogenic therapy in ocular disease--current and future strategies].
    Agostini H; Feltgen N; Hansen L
    Klin Monbl Augenheilkd; 2008 Jan; 225(1):39-43. PubMed ID: 18236368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and nondiabetic subjects.
    García-Ramírez M; Hernández C; Simó R
    Diabetes Care; 2008 Jun; 31(6):1189-94. PubMed ID: 18332162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression pattern of erythropoietin and erythropoietin receptor in experimental model of retinal detachment.
    Xie Z; Wu X; Qiu Q; Gong Y; Song Y; Gu Q; Li C
    Curr Eye Res; 2007 Sep; 32(9):757-64. PubMed ID: 17882708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging technologies in the delivery of erythropoietin for therapeutics.
    Murua A; Orive G; Hernández RM; Pedraz JL
    Med Res Rev; 2011 Mar; 31(2):284-309. PubMed ID: 19967731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Raves and risks for erythropoietin.
    Maiese K; Chong ZZ; Shang YC
    Cytokine Growth Factor Rev; 2008 Apr; 19(2):145-55. PubMed ID: 18299246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial and ominous aspects of the pleiotropic action of erythropoietin.
    Jelkmann W; Wagner K
    Ann Hematol; 2004 Nov; 83(11):673-86. PubMed ID: 15322761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.